Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 4/20 | 0.39 |
| ▸ | CCR8 | P51685 | 4/20 | 0.39 |
| ▸ | CCR5 | P51681 | 2/20 | 0.39 |
| ▸ | CASP6 | P55212 | 2/20 | 0.39 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.39 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | MMP2 | P08253 | 2/20 | 0.38 |
| ▸ | GMNN | O75496 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14122788 | 0.80 | CCR1 (0.36) | CCR1CCR8CCR5CASP6PSMD14 | |
| SCHEMBL487383 | 0.76 | TLR7 (0.50) | CCR1CCR8CCR5PSMD14COPS5 | |
| SCHEMBL4299811 | 0.74 | TLR7 (0.42) | CCR1CCR8CCR5HSP90AA1KDM4E | |
| SCHEMBL4704097 | 0.73 | LMNA (0.50) | CCR1CCR8CCR5PSMD14COPS5 | |
| SCHEMBL2478261 | 0.70 | PSMD14 (0.62) | CCR1CCR8CCR5CASP6PSMD14 | |
| SCHEMBL7548538 | 0.70 | KDM4E (0.52) | CCR1CCR8CCR5CASP6PSMD14 | |
| SCHEMBL4953265 | 0.69 | ALDH1A1 (0.32) | HSP90AA1HSP90AB1L3MBTL1IDO1PSMB5 | |
| SCHEMBL2471617 | 0.68 | SLC40A1 (0.47) | CCR1CCR8CCR5CASP6PSMD14 | |
| SCHEMBL139256 | 0.68 | CCR1 (0.61) | CCR1CCR8CCR5CASP6HSP90AA1 | |
| SCHEMBL16550189 | 0.67 | ALDH1A1 (0.62) | CCR1CCR8CCR5CASP6HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070167479-A1 | Immune response modifier formulations and methods | BAUSCH HEALTH COMPANIES INC. (CA) | 2007-07-19 | — | — | US | claimed |
| EP-1729768-A2 | IMMUNE RESPONSE MODIFIER FORMULATIONS AND METHODS | 3M Innovative Properties Company (US) | 2006-12-13 | — | — | EP | claimed |
| WO-2005089317-A2 | IMMUNE RESPONSE MODIFIER FORMULATIONS AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-09-29 | — | — | WO | claimed |
| EP-1729768-B1 | IMMUNE RESPONSE MODIFIER FORMULATIONS AND METHODS | MEDA AB (SE) | 2018-01-10 | — | — | EP | disclosed |
| US-8110582-B2 | by administering immune response modifier compounds | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-02-07 | — | — | US | disclosed |
| US-20070167479-A1 | Immune response modifier formulations and methods | BAUSCH HEALTH COMPANIES INC. (CA) | 2007-07-19 | — | — | US | disclosed |
| EP-1729768-A2 | IMMUNE RESPONSE MODIFIER FORMULATIONS AND METHODS | 3M Innovative Properties Company (US) | 2006-12-13 | — | — | EP | disclosed |
| EP-1601365-A2 | PROPHYLACTIC TREATMENT OF UV-INDUCED EPIDERMAL NEOPLASIA | 3M Innovative Properties Company (US) | 2005-12-07 | — | — | EP | disclosed |
| WO-2005089317-A2 | IMMUNE RESPONSE MODIFIER FORMULATIONS AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-09-29 | — | — | WO | disclosed |
| WO-2004078138-A2 | PROPHYLACTIC TREATMENT OF UV-INDUCED EPIDERMAL NEOPLASIA | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2004-09-16 | — | — | WO | disclosed |
| US-20040175336-A1 | Prophylactic treatment of UV-induced epidermal neoplasia | 3M INNOVATIVE PROPERTIES COMPANY | 2004-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167479-A1 | Immune response modifier formulations and methods | IFNG, TLR5, ICOS | CCR1 722/4885CCR8 741/4885CCR5 946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.